Docket No.: GNE.2930R1C2



## INFORMATION DISCLOSURE STATEMENT

icant : Botstein, et al.

App. No : 10/033,244

Filed: December 27, 2001

For : SECRETED AND

TRANSMEMBRANE POLYPEPTIDES

AND NUCLEIC ACIDS ENCODING

THE SAME

Examiner: Fredman, Jeffrey N.

Art Unit : 1637

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

May 13, 2005 (Date)

AnneMarie Kaiser, Reg. No. 37,649

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is an Information Disclosure Statement by Applicant (PTO/SB/08 equivalent) listing 37 references to be considered by the Examiner. Also enclosed are 24 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed within three months of the filing date, with an RCE or before receipt of a first office action after an RCE and no fee is required.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

By:

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated:

Anne Marie Kaiser

Registration No. 37,649

Attorney of Record Customer No. 30,313

(619) 235-8550

1711732 051305

INFORMATION DISCLOS  MAY 1 6 2005  STATEMENT BY APPLIC			
۲	(Multiple sheets used when necessary)	_	
	SHEET 1 OF 2		
		_	

6,562,343

6,645,499

6,730,502

6,737,522

10

11

12

13

	Application No.	10/033,244
	Filing Date	December 27, 2001
First Named Inventor		Botstein, et al.
	Art Unit	1637
	Examiner	Fredman, J.
	Attorney Docket No.	GNE.2930R1C2

••••						
			U.S. PATENT	DOCUMENTS		
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	
	1	6,025,156	02-15-2000	Gwynn, et al.		
	2	6,124,433	09-26-2000	Falb, et al.		
	3	6,156,500	12-05-2000	Falb, Dean		
	4	6,162,604	12-19-2000	Jacob, Chaim O.		
	5	6,228,582	05-08-2001	Rodier, et al.		
	6	6,395,306	05-28-2002	Cui, et al.		
	7	6,414,117	07-02-2002	Levinson, D. A.		
	8	6,465,185	10-15-2002	Goldfine, et al.		
	9	6,498,235	12-24-2002	Sheppard, et al.		

05-13-2003

11-11-2003

05-04-2004

05-18-2004

Levinson, D. A.

Van Hijum, et al.

Sundick, et al.

Lal, et al.

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T¹		
	14	ALBERTS, et al. 1994. <i>Molecular Biology of the Cell, 3rd Edition</i> , pp. 403-404, 453. New York: Garland Publishing.			
	15	ALBERTS, et al. 2002. <i>Molecular Biology of the Cell 4th Edition</i> , pp. 302, 363-364, 379, 435. New York: Garland Publishing.			
	16	ALITALO 1984. Amplification of cellular oncogenes in cancer cells. Med. Biol., 62:304-317			
	17	BANHASSY, et al. 2004. Cyclin A and cyclin DI as significant prognostic markers in colorectal cancer patients. <i>BMC Gastroenterology</i> , 4:22-34.			
	18	BIECHE, et al. 1998. Novel Approach to Quantitative Polymerase Chain Reaction Using Real-Time Detection: Application to the Detection of Gene Amplification in Breast Cancer. <i>Int. J. Cancer.</i> 78:661-666.			
	19	BLANCATO, et al. 2004. Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridization and immunohistochemical analyses. British Journal of Cancer, 90(8), 1612-1619.			
_	20	GRIMALDI, et al. 1989. The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. <i>Blood</i> , 73(8):2081-2085.			

Ex	aminer Signature	Date Considered
<u> </u>		

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

	156		PTO/SB/08 Equivalent
/	OILE	Application No.	10/033,244
Γ,	INFORMATION DISCLOSURE	Filing Date	December 27, 2001
<b>,</b>	MAY 1 6 2005 STAMEMENT BY APPLICANT	First Named Inventor	Botstein, et al.
		Art Unit	1637
<b>V</b>	SHEET 2 OF 2	Examiner	Fredman, J.
	SHEET 2 OF 2	Attorney Docket No.	GNE.2930R1C2

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	21	GYGI, et al. Mar. 1999. Correlation between Protein and mRNA Abundance in Yeast. Molecular and Cellular Biology, 1720-1730.	
	22	HANNA, et al. Aug. 1999. HER-2/neu breast cancer predictive testing. <i>Pathology Associates Medical Laboratories</i> .	
	23	HEID, et al. 1996. Real Time Quantitative PCR. Genome Res. 6:986-994.	
	24	HIGUCHI, et al. April 1992. Simultaneous Amplification and Detection of Specific DNA Sequences. <i>Biotechnology</i> , 10:413-417.	
	25	HYMAN et al. Nov. 2002. Impact of DNA Amplification of Gene Expression Patterns. Cancer Research, 62:6240-6245.	
	26	LEWIN, B. 1994. Oncogenes: Gene Expression and Cancer, Chap. 39, pp.1196-1201. Genes V. New York: Oxford University Press.	
	27	LEWIN, B. 1997. Regulation of Transcription, Chap. 29, pp. 847-848. <i>Genes VI</i> . New York: Oxford University Press.	
	28	LIVAK, et al. 1995. Oligonucleotides with Fluerescen Dyes at Opposite Ends Provide a Quenced Probe Statem Useful for Detectin PCR Product and Nucleic Acid Hybridization. <i>PCR Methods Appl</i> 4:357-362.	
	29	MEEKER, et al. 1990. Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia. <i>Blood</i> , 76(2):285-289.	
	30	MERIC, et al. 2002. Translation initiation in cancer: A novel target for therapy. <i>Molecular Cancer Therapeutics</i> , 1:971-979.	
	31	MERLINO, et al. 1985. Elevated Epidermal Growth Factor Receptor Gene Copy Number and Expression in a Squamous Carcinoma Cell Line. <i>J. Clin. Invest.</i> , 75:1077-1079	
	32	ØRNTOFT, et al. 2002. Genome-wide study of gene copy numbers, transcripts, and protein levels in pairs of non-invasive and invasive human transitional cell carcinomas. <i>Molecular &amp; Cellular Proteomics</i> , 1:37-45.	
	33	PENNICA, et al. 1998. WISP genes are members of the connective tissue growth factor family that are up-regulated in Wnt-1 transformed cells and aberrantly expressed in human colon tumors. <i>Proc. Natl. Acad. Sci. USA</i> . 95(25):14717-14722.	
	34	PITTI, et al., 1998. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. <i>Nature</i> . 396(6712):699-703.	
	35	POLLACK, et al. 2002. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. <i>PNAS</i> , 99(20):12963-12968.	
	36	SINGLETON, et al. 1992. Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene. Pathol. Annu, 1(27):165-190.	
	37	ZHIGANG, et al. 2004. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer. World Journal of Surgical Oncology, 2:13.	

1711665 051305

	Examiner Signature	Date Considered		
ı		with MADED COO. Draw line About heitetien if not		

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.